TransThera Sciences Seeks HK$156 Million via Share Offering

MT Newswires Live05-19

TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.

The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.

The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.

TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.

Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636885855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636885855","market":"sg","top_or_hot":-1,"title":"TransThera Sciences Seeks HK$156 Million via Share Offering","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.</p><p>The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.</p><p>TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.</p><p>Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences Seeks HK$156 Million via Share Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences Seeks HK$156 Million via Share Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.</p><p>The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.</p><p>TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.</p><p>Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636885855","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636885855","pubTimestamp":1779154686,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The drugmaker is seeking investors ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02617":"药捷安康-B"},"translate_title":"Tranthera Sciences通过股票发行寻求1.56亿港元","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The drugmaker is seeking investors for 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product tinengotinib.The shares represent 1.24% of the company's existing H shares and 0.95% of its total issued shares, and 1.23% and 0.94% as enlarged by the offering, respectively.TransThera recently said that tinengotinib was found to offer benefit to patients in a clinical trial conducted in China.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636885855","isCrawlerRequest":true}